

Special Issue

Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers

Message from the Guest Editor

The human papillomavirus (HPV) has not only been associated with cervical cancer but with other tumors in men, as well as in women. HPV-related premalignant and malignant lesions have been demonstrated in the oropharyngeal, vagina, vulva, anus, and penis. The burden of disease HPV-related is wide and implies an elevated sanitary cost. Nowadays, we count the vaccines against HPV as primary prevention, but HPV determination as secondary prevention is only demonstrated in cervical cancer screening. In addition, there is no HPV-directed treatment, we can only treat the associated lesion, and the immune system is the unique way to clear the infection. HPV persistence and latency and how the biological behavior in each site of infection are today non-resolved issues. New research related to HPV prevention, diagnosis, management, and treatment is necessary to improve the knowledge about HPV infection and its consequences in women and men, especially in special population as immunosuppressed.

Guest Editor

Dr. Pluvio J. Coronado

1. Department of Obstetrics and Gynecology, Complutense University of Madrid, Madrid, Spain
2. Head of Gynecology Oncology Unit, Hospital Clinico San Carlos, Madrid, Spain

Deadline for manuscript submissions

closed (25 September 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/114136

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).